Serologicals Corporation to Present at JPMorgan Small Cap Conference

Serologicals Corporation (NASDAQ: SERO) today announced
that it is scheduled to give an investor presentation at the JPMorgan
Small Cap Conference on November 2, 2005.
   Bud Ingalls, Vice President, Finance and Chief Financial Officer
for Serologicals Corporation, will be making the presentation,
scheduled for 8:00 a.m. (ET) at The Four Seasons Hotel in Boston, MA.
The presentation will be web cast live (audio only) and can be
accessed through the Company's website at www.serologicals.com, or at
http://equityconferences.jpmorgan.com.

   Serologicals Corporation (NASDAQ: SERO), headquartered in Atlanta,
GA., is a global leader in developing and commercializing consumable
biological products, enabling technologies and services in support of
biological research, drug discovery, and the bioprocessing of
life-enhancing products. Our customers include researchers at major
life science companies and leading research institutions involved in
key disciplines, such as neurology, oncology, hematology, immunology,
cardiology, proteomics, infectious diseases, cell signaling and stem
cell research. In addition, Serologicals is the world's leading
provider of monoclonal antibodies for the blood typing industry.
   Serologicals employs a total of more than 1,000 people worldwide
in three Serologicals' companies: Chemicon International,
headquartered in Temecula, California, Upstate Group, LLC,
headquartered in Charlottesville, Virginia and Celliance Corporation,
headquartered in Atlanta Georgia.
   For more information, please visit our website:
www.serologicals.com.